GreenLight Biosciences Fundraise: US$102M From Morningstar, Others

greenlight biosciences fundraise

Malaysian government’s Xeraya Capital also participated in GreenLight Biosciences’ fundraise

U.S.-based biotechnology company GreenLight Biosciences has raised $102 million in its Series D round fundraise from large Southeast Asian and American investors, the company announced in a statement.

The oversubscribed round was led by Hong Kong-based Morningside Ventures, owned by the Chan family, the real-estate family business behind property developer group Hang Lung, with participation from a host of new and existing investors.

Malaysian government-owned Xeraya Capital also participated in the fundraise via MLS Capital Fund II, a biogreentech fund co-managed by Spruce Capital Partners and Xeraya Capital.

Xeraya Capital had earlier invested in GB’s $17 million ‘special purpose funding round’ to grow production capacity for possible Covid-19 vaccines, including those based ribonucleic acid (RNA).

Other investors in the Series D round included S2G Ventures, Cormorant Asset Management, Continental Grain Company, Fall Line Capital, Tao Capital Partners, Baird Capital (who also participated in the $17 million round), Lewis and Clark Agrifood, and Lupa Systems, all of whom are based in the U.S.

“GreenLight Biosciences’ manufacturing technology can address critical pain points for RNA supply in both agriculture and human health,” Morningside Ventures Investment Advisor and Intellectual Property Counsel Jason Dinges said in the statement.

He added that RNA products are an avenue for innovation in human therapeutics and environment-friendly agriculture.

The fresh capital will be used to expand production of the company’s RNA products, which include new RNA-based therapies, to create sustainable solutions in health sciences and agriculture.

[RNA is a biological macromolecule](https://www.rnasociety.org/what-is-rna#:~:text=Ribonucleic acid%2C or RNA is,DNA makes RNA makes protein”.) that helps synthesize the genetic information present in DNA into proteins. In some cases, RNA can carry viral genetic information and has been connected to human diseases such as heart disease, stroke, and some types of cancer.

The funding will also drive development and commercialization of the company’s sustainable agriculture products. GreenLight Biosciences is expecting to launch its first biopesticide in 2022.

“GreenLight was born from a passion to make our world more sustainable and more equitable,” GreenLight Biosciences Co-founder and CEO Andrey Zarur said in the statement. “We remain steadfast in our commitment to provide bio-based solutions for plant health, human health and animal health, and to make those solutions affordable and accessible.”

The company has been raised capital in a sequence of Series D tranches from 2017, when it first raised a $18 million Series D round in September 2017 led by Fall Line Capital, with five other participating investors including Lewis and Clark Ventures and S2G Ventures.

More recently, it also raised $50 million in a venture round led by S2G Ventures and Baird Capital in January 2019, with participation from five other investors including Tao Capital Partners and Continental Grain Company.

Overall, the 2008-founded company has raised a total corpus of $215 million in eight rounds since 2013.

Header image by Martin Lopez from Pexels

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email
Sharon Lewis
Sharon is a Staff Writer at Jumpstart

RELATED POSTS

Why Is the Metaverse Important for Your Brand

Why Is the Metaverse Important for Your Brand?

Metaverse is the older–and much more advanced–sibling of the internet, and it is on its way to becoming the favorite child of many brands. It is a new iteration of the web that is shaped by its users.

Top 5 Electric Car Companies of 2022

Top 5 Electric Car Companies of 2022

Business and political conversations in recent years have shown that you simply cannot talk about progress without mentioning sustainability. Startups and big corporations are having to upgrade their business models to factor in climate change and the environment. Shoppers have taken notice, too.

Asian Startups Set to Join the IPO Race in 2022

Asian Startups Set to Join the IPO Race in 2022

Despite the pandemic, 2021 had been a bumper year for initial public offerings (IPOs). According to the 2021 EY (Ernst & Young) Global IPO Trends Report, the global IPO market had a total of 2,388 IPO deals, raising US$453.3 billion in proceeds. Global IPO activity was up 64 percent in deal numbers and 67 percent in proceeds when compared to 2020.

How-To Tech Safe Internet Navigation Tips for Seniors

How-To Tech: Safe Internet Navigation Tips for Seniors

As you get older, it gets harder and harder to keep up with the advances in technology. Also, cybercriminals are exploiting the pandemic-induced shift to the digital realm to their benefit. The elderly lose US$30 billion a year to online scams, and as of 2020, there has been a 69% increase in online scam reports.

Why Are Jack Dorsey and Elon Musk against Web 3.0

Why Are Jack Dorsey and Elon Musk against Web 3.0?

“Sounds like BS” was Tesla CEO Elon Musk’s very eloquent review of Web 3.0. After all, few people know more about BS than Musk.
Web 3.0 has been touted as the internet of the future and a new generation of webs. It aspires to decentralize the internet using blockchain-based tokens. It will allow people to “own” their internet activities, thus doing away with the power of big techs, such as Amazon, Alphabet and the like.

Virtual Concerts—The Post-COVID Future of the Music Industry

Virtual Concerts—The Post-COVID Future of the Music Industry

Much like most other industries, the music industry also saw a hefty blow from the pandemic. Be it BTS, the Weeknd, Harry Styles or Bon Jovi, a lot of major artists have had to cancel their concerts throughout 2020. To make up for these canceled live interactions with fans, artists shifted to the Internet.